Abstract: This invention relates to drugs that lead to express proteins involved in redox regulation that antagonize oxidative stresses, which elicit inflammation, alleviate inflammation and thus protect living body.

Abstract: Disclosed is a specific identification method of an MRSA and MRC-NS, which is speedy, simple and reliable. Specifically, the present invention provides a diagnostic method of an MRSA or MRC-NS, which comprises performing a reaction with a sample by making combined use of a part of a mecDNA, which is an integrated adventitious DNA existing on a chromosome of the MRSA or MRC-NS and carrying an mecA gene thereon, and a part of a nucleotide sequence of a chromosomal DNA surrounding the integrated DNA; and also a diagnostic method of an MRSA or MRC-NS by PCR, LCR or hybridization, which comprises performing a reaction with a sample by using a nucleotide sequence of a chromosomal DNA surrounding an integrated site of a mecDNA in a chromosome of an MSSA or MSC-NS, wherein said method makes use of an occurrence of a negative reaction when said sample contains a mecDNA integrated therein.

Abstract: The present invention provides a method for the screening of a wound-healing agent, which comprises determining a substance to be active as a wound-healing agent on the basis of potentiation or modification of biological activities of a growth and/or differentiation factor, a growth hormone or a cytokine. This invention also provides a wound-healing method, which comprises as an active ingredient a compound of the following formula (1) or formula (2) found to be active by the screening method.

Abstract: The present invention relates to pyrimidine compounds represented by the formula ##STR1## (wherein X is a substituted or a cyclic amino group and Y is a substituted amino group or a substituted carbonyl group) or their pharmaceutically acceptable salts, and a therapeutic agent for neurological diseases comprising the compounds.These compounds are useful for treatment of various disorders in nervous systems since they are effective on growth of neurons and promotion of the formation and elongation of neutrites.

Abstract: A medicament for prevention and remedy of diseases caused by the infection of viruses is disclosed, which is characterized by containing as an effective ingredient thereof a nonapeptide having the following amino acid configuration:pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn or an ester and an amide at the carboxyl group of the C-terminal of the asparagine or a pharmacologically acceptable salt thereof.

Abstract: This invention provides novel pyrimidines or their pharmaceutically acceptable salts thereof and process for preparation thereof. The novel compounds are useful for neurological diseases of the peripheral and central nervous systems of animals.

Abstract: Disclosed herein are phosphoric acid esters of myoinositol, which are represented by the following general formula (I): ##STR1## and their salts, as well as a preparation process thereof. The myoinositol derivatives can each be obtained by causing a phosphorylating agent to act on a myoinositol derivative substituted with catalytic reduction removable substituent groups at the positions other than those desired to be substituted by phosphoric acid residual groups and then catalytically reducing the thus-phosphorylated myoinositol.

Abstract: A medicament for prevention and remedy of diseases of pancreas and others is disclosed, which is characterized by containing as an effective ingredient thereof a nonapeptide having the following amino acid configuration:pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asnor an ester and amide at the carboxyl group of the C-terminal of the asparagine or a pharmacologically acceptable salt thereof.

Abstract: 2,6-di-, 2,4,6-, 2,5,6-tri- or 2,4,5,6-tetra-substituted pyrimidines, and 2,6-di-substituted pyridines. These compounds are useful for treatment of neurological deseases.

Abstract: There are disclosed a novel inositol-1,4,5-triphosphoric acid derivative, inositol-1,3,4-triphosphoric acid derivative, inositol-1,3,4,5-tetraphosphoric acid derivative, and a bonded substance of the same and a protein. They control the metabolic process of an organism concerned with calcium ions to thereby exert a medicinal virtue.

Abstract: B cell differentiation factor which acts on B cells and participates in their differentiation into antibody-producing cells is produced by an established cell line.

Abstract: Amine represented by the following formula (1), or their acid addition salts or their quaternary ammonium salts. ##STR1## The amines of formula (1) or their pharmaceutically acceptable acid addition salts or quaternary ammonium salts are useful for the treatment and prevention of heart diseases of animals, particularly arrhythima, myocardial infarction, angina pectoris and heart failure and psychoneurological diseases.

Abstract: 2,6-di-, 2,4,6-, 2,5,6-tri- or 2,4,5,6-tetra-substituted pyrimidines, and 2,6-di-substituted pyridines. These compounds are useful for treatment of neurological diseases.

Abstract: A novel established cell line, KML.sub.1-7, obtained by collecting lymphoid cells from an animal with autoimmune disease, culturing them in a culture medium containing the supernatant of a culture in which lymphoid cells of animal origin have been grown in the presence of a mitogen, and continuing the culture for a period of 8 months until the cells are able to grow in the absence of the aforesaid supernatant. This established cell line has the following properties.(1) It produces a factor, B-Cell Differentiation Factor (BCDF), participating in the differentiation of antibody-producing cells.(2) It does not produce B cell growth factor.(3) It consists of immortalized null cells.

Abstract: A sialic acid-bonded octapeptide represented by the following general formula (I): ##STR1## wherein R represents a hydrogen atom or an acetyl group; and R' represents a lower alkyl group, an aralkyl group, a hydrogen atom or an alkali metal atom, is herein disclosed. The peptide chain of the sialic acid-bonded octapeptide is constituted by 8 amino acid molecules on the C-terminus side of FTS and the compounds represented by formula (I) can be obtained by bonding sialic acid to the amino terminus of the peptide chain according to condensation. These octapeptides show excellent physiological activity comparable to FTS and a half life in blood longer than that of FTS and it is expected that the affinity of the peptide to lymphocytes is also enhanced. Thus they can effectively be used as medicines for treating the lowering and abnormality of functions of the thymus.

Abstract: A pharmaceutical composition comprising a pyrimidine represented by the following formula ##STR1## wherein R.sup.1 represents a hydrogen atom, an acyl group having 2 to 4 carbon atoms, an alkoxycarbonyl group having 2 to 5 carbon atoms, an alkoxycarbonylmethyl group having 3 to 5 carbon atoms, a 3,4-dimethoxybenzoyl group or a 3,4-methylenedioxybenzyl group,R.sup.2 represents a hydrogen atom, an amino group, a monoalkylamino group having 1 to 4 carbon atoms, an alkoxy group having 1 to 5 carbon atoms or an alkoxycarbonyl group having 2 to 4 carbon atoms,R.sup.3 represents a hydrogen atom, an alkoxycarbonyl group having 2 to 4 carbon atoms, a dialkylaminocarbonyl group having 1 to 9 carbon atoms in each alkyl moiety, an alkoxy group having 1 to 5 carbon atoms, or a hydroxyethyl group, R.sup.2 and R.sup.3, together with the carbon atoms to which they are bonded, may form a 5- to 7-membered carbocyclic ring or a heterocyclic ring having N, O or S as the hetero atom, and R.sup.

Abstract: Disclosed herein are phosphoric acid esters of myoinositol, which are represented by the following general formula (I): ##STR1## and their salts, as well as a preparation process thereof. The myoinositol derivatives can each be obtained by causing a phosphorylating agent to act on a myoinositol derivative substituted with catalytic reduction removable substituent groups at the positions other than those desired to be substituted by phosphoric acid residual groups and then catalytically reducing the thus-phosphorylated myoinositol.

Abstract: The present invention relates to cyclohexanone derivatives represented by general formula: ##STR1## wherein R represents a hydrogen atom or an acetyl group. The cyclohexanone derivatives are important intermediates for producing isoquinoline derivatives which are useful as drugs, especially for heart drugs.

Abstract: An isoquinoline derivative of the following formula: ##STR1## wherein R.sub.1 is a methyl or a methoxymethyl group and R.sub.2 and R.sub.3 are each a hydrogen atom or a methyl, ethyl, methoxy, a cyclohexyl, a phenyl, a 3,4-dimethoxyphenyl, a pyridyl or an oxo (.dbd.O) group;and therapeutically acceptable salts thereof which exhibit a low toxicity and a wide range of safety and are highly useful as a cardiotonic medication.

Abstract: Disclosed herein is an antihypertensive preparation containing, as an active component, a novel quinazoline derivative represented by the following general formula or a salt thereof: ##STR1## wherein R.sup.100 means a hydrogen atom or methoxy group, R.sup.200 and R.sup.300 denote individually a hydrogen atom or lower alkoxy group, R.sup.400 is a hydrogen atom or amino group, l stands for 2 or 3, and Het is a specific hetero ring group.